Post-merger immunology rollup with RMAT-designated briquilimab approaching BLA, contingent on FDA accepting the SCID dataset as registration-quality

Jasper Therapeutics is a clinical-stage immunology company whose lead program, briquilimab, targets severe combined immunodeficiency (SCID), a fatal inherited immune disorder in infants, and is not yet approved.

The Jasper-Kira merger created a three-asset immunology pipeline anchored by briquilimab, an anti-KIT antibody with RMAT designation targeting SCID, a fatal immune disorder in infants with no broadly approved gene-agnostic therapy. The thesis resolves on whether FDA accepts briquilimab's existing SCID dataset as a BLA basis, confirmed at the Q1 2027 pre-BLA meeting. KP-104, a bifunctional complement inhibitor in PNH and rare renal disorders, adds optionality but remains in Phase 2 with no confirmed registrational path.